FDA approves abiraterone acetate for treatment of castration-sensitive, metastatic prostate cancer

Late yesterday the US Food and Drug Administration announced the approval of abiraterone acetate (Zytiga) + prednisone for the treatment of men with “high-risk, castration-sensitive”, metastatic prostate cancer. … READ MORE …

What did you hope to learn from your genetic test … if you have ever had one?

There’s a very nice article today on the MedPage Today web site about the medical value of “at-home genetic testing” (i.e., the sorts of tests available from companies like 23&Me and some others). … READ MORE …

Long-term follow-up data from the CHAARTED trial

At the time of the original presentation of data from the CHAARTED trial, the median follow-up for patients enrolled in this trial was 28.9 months. We now have data from the same 790 patients followed for a median of 53.7 months. … READ MORE …

Mental health and ADT: an objective review

As regular readers will be aware, there has been some intense debate over the past year or so about whether there is an association between treatment with androgen deprivation therapy (ADT) and risk for dementia. … READ MORE …

Molecular biological reasons for switching to a healthier diet!

Two articles just published this week by a Boston-based research team have implicated Western high-fat diets in risk for metastasis of prostate cancer. … READ MORE …

Your genetics can accurately predict your age-related prostate cancer risk

Data from a new study reported in the British Medical Journal discusses a “polygenic hazard score” that can potentially be used to guide screening for aggressive prostate cancer (but only in men of European ancestry at this time). … READ MORE …

PET/MRI scanning in pre-surgical staging of high-risk prostate cancer patients

A small, Norwegian, Phase II clinical trial has explored the potential diagnostic value of [18F]fluciclovine PET/MRI scans of the pelvic lymph nodes in staging for patients with high-risk prostate cancer. … READ MORE …